Overview
At a Glance
Melanotan II (MT-II) is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production in the skin, producing a tan without significant UV exposure. It also triggers sexual arousal and suppresses appetite. MT-II is not approved by the FDA or any major regulatory agency for any indication. It is sold through grey-market research chemical vendors and self-administered by injection. Health authorities worldwide have issued warnings against its use due to unknown long-term safety, contamination risks, and concerns about melanocytic changes that may complicate skin cancer screening.
- Melanotan II has not been approved by the FDA, EMA, TGA, or any major regulatory body for any medical or cosmetic indication
- It has not completed the clinical trial process required to establish safety and efficacy
- All supply comes from unregulated sources with no guarantee of purity, sterility, or accurate dosing
- Multiple national health agencies — including the FDA, TGA (Australia), and MHRA (UK) — have issued explicit warnings against its use
- This article is provided for harm reduction and education only, not as an endorsement of use
Melanotan II was originally developed in the 1990s at the University of Arizona by researchers investigating synthetic analogues of α-MSH as potential sunless tanning agents. The goal was to create a compound that could stimulate melanocytes — the pigment-producing cells in the skin — to produce melanin without UV radiation exposure. This was conceived as a potential strategy for skin cancer prevention, since melanin provides some natural photoprotection (Hadley et al., 1996).
During early clinical testing, researchers observed an unexpected side effect: pronounced sexual arousal and spontaneous erections in male subjects. This observation led to the development of a derivative compound, bremelanotide (PT-141), which was engineered to maximize sexual function effects while minimizing tanning activity. PT-141 eventually became FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women (Diamond et al., 2005).
Melanotan II itself, however, was never pursued through the full regulatory approval process. Instead, it entered an underground market where it is sold as a "research chemical" or "not for human consumption" — legal fictions that allow vendors to distribute it without regulatory oversight. It is primarily used by individuals seeking cosmetic tanning, though some users also report using it for its sexual arousal or appetite-suppressive effects.
The compound is self-administered via subcutaneous injection, typically reconstituted from a lyophilized (freeze-dried) powder purchased online. This means users are injecting a substance of unknown purity, unknown sterility, and unknown dosing accuracy — a risk profile fundamentally different from any FDA-approved injectable medication.
Quick Facts
| Property | Details |
|---|---|
| Chemical name | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 |
| Molecular formula | C50H69N15O9 |
| Molecular weight | 1,024.18 Da |
| Target receptors | MC1R, MC3R, MC4R, MC5R (non-selective melanocortin agonist) |
| Primary effect | Melanogenesis (skin tanning) via MC1R |
| Secondary effects | Sexual arousal (MC4R), appetite suppression (MC4R), penile erection |
| Route | Subcutaneous injection |
| FDA status | Not approved for any indication |
| Derivative | PT-141 (bremelanotide / Vyleesi) — FDA-approved for HSDD |
| Related compound | Afamelanotide (Melanotan I / Scenesse) — approved for EPP |
This content is for informational and harm-reduction purposes only. It does not constitute medical advice or endorsement of use. Consult a healthcare provider before using any peptide.
How It Works
The Melanocortin System
The melanocortin system comprises a family of peptide hormones (α-MSH, β-MSH, γ-MSH, ACTH) and five receptor subtypes (MC1R–MC5R). Each receptor serves different physiological roles:
- MC1R: Expressed on melanocytes in the skin. Activation stimulates eumelanin (dark pigment) production. This is the receptor responsible for tanning and is the primary target of Melanotan II's cosmetic effect (Hadley & Dorr, 2006).
- MC3R: Expressed in the hypothalamus and peripheral tissues. Involved in energy homeostasis and sexual behavior. Contributes to MT-II's effects on arousal and appetite (Molinoff et al., 2003).
- MC4R: Expressed predominantly in the hypothalamus and limbic system. Critical for appetite regulation, sexual arousal, and erectile function. Activation of MC4R is responsible for MT-II's pro-sexual effects and appetite suppression. It is also the receptor through which nausea is mediated (Molinoff et al., 2003).
- MC5R: Expressed in exocrine glands and other tissues. Role less well characterized. May contribute to sebaceous gland function.
Unlike its derivative PT-141 (bremelanotide), which was engineered for greater MC4R selectivity, Melanotan II activates all four receptor subtypes with relatively similar potency. This non-selectivity is why MT-II produces tanning, sexual arousal, appetite suppression, nausea, and other effects simultaneously — it is pharmacologically "blunt" (Wikberg et al., 2001).
Melanogenesis: How Tanning Occurs
When Melanotan II binds to MC1R on melanocytes, it triggers an intracellular signaling cascade:
- MC1R activation stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP)
- Elevated cAMP activates protein kinase A (PKA)
- PKA phosphorylates CREB (cAMP response element-binding protein), which translocates to the nucleus
- CREB activates transcription of the MITF gene (microphthalmia-associated transcription factor)
- MITF drives expression of melanogenic enzymes: tyrosinase, TRP-1, and TRP-2
- These enzymes catalyze the conversion of tyrosine to eumelanin (brown-black pigment)
- Melanin is packaged into melanosomes and transferred to surrounding keratinocytes, producing visible skin darkening
This process takes days to weeks to produce visible tanning. Some minimal UV exposure may accelerate the response by activating melanocytes and increasing MC1R expression, though MT-II can produce tanning even without UV exposure in some individuals (Dorr et al., 2000).
Sexual Arousal Pathway
MT-II's sexual effects are mediated through MC4R (and possibly MC3R) activation in the hypothalamus, particularly in the medial preoptic area and paraventricular nucleus. This triggers downstream release of dopamine and oxytocin — neurotransmitters associated with sexual motivation and arousal. In men, MC4R activation in the paraventricular nucleus also triggers pro-erectile signaling through spinal pathways, explaining the spontaneous erections commonly reported with MT-II use (Diamond et al., 2005).
Why Non-Selectivity Matters
The key pharmacological distinction between Melanotan II and its derivatives (PT-141, afamelanotide) is receptor selectivity:
| Compound | MC1R (Tanning) | MC4R (Sexual/Appetite) | Selectivity | Regulatory Status |
|---|---|---|---|---|
| Melanotan II | Strong | Strong | Non-selective | Not approved |
| Afamelanotide (MT-I) | Strong | Weak | MC1R-selective | FDA-approved (EPP) |
| Bremelanotide (PT-141) | Moderate | Strong | MC4R-preferring | FDA-approved (HSDD) |
Sources: Wikberg et al., 2001 · Molinoff et al., 2003
This non-selectivity means that every user seeking tanning also receives sexual stimulation, appetite changes, nausea, and — critically — broad melanocyte activation that can darken moles and potentially promote melanocytic proliferation. It is precisely this lack of selectivity that led pharmaceutical development away from MT-II and toward more targeted derivatives.
Go Deeper
- Hadley & Dorr (2006) — "Melanocortin peptide therapeutics: historical milestones" — Peptides
- Wikberg et al. (2001) — "New aspects on the melanocortins and their receptors" — Pharmacological Research
- Molinoff et al. (2003) — "PT-141: A melanocortin agonist for sexual dysfunction" — Annals of the NY Academy of Sciences
This content is for informational purposes only and does not constitute medical advice.
Evidence
Clinical Trial Data
The formal clinical evidence base for Melanotan II is thin compared to approved peptides. Key studies include:
| Study | Design | Key Findings |
|---|---|---|
| Dorr et al., 1996 | Phase I, 3 subjects, escalating SC doses | First human study. Demonstrated dose-dependent tanning in fair-skinned subjects. Significant nausea, facial flushing, and fatigue at higher doses. One subject experienced spontaneous erection. |
| Dorr et al., 2000 | Phase I, 10 men, 0.025 mg/kg SC × 10 days | Significant increase in melanin density measured by reflectance spectroscopy. Tanning achieved without UV exposure. Nausea in 85% of subjects. Spontaneous erections in multiple subjects. Yawning and stretching observed. |
| Hadley & Dorr, 2006 | Review of University of Arizona clinical program | Summarized decade of MT-II research. Confirmed tanning efficacy and sexual side effects. Noted that pharmaceutical development shifted to more selective analogues (afamelanotide, PT-141) due to MT-II's non-selectivity and complex side effect profile. |
Sources: Dorr et al., 1996 · Dorr et al., 2000 · Hadley & Dorr, 2006
Case Reports and Adverse Event Data
Since Melanotan II never completed clinical development, most real-world safety data comes from case reports of adverse events in self-administering users:
| Report | Event | Details |
|---|---|---|
| Peters et al., 2020 | Renal infarction | A previously healthy man developed renal infarction attributed to MT-II use. Authors proposed thrombotic pharmacological effects and possible direct renal toxicity. |
| Habbema et al., 2017 | Melanocytic changes (review) | Comprehensive review documenting darkening of existing moles, emergence of new nevi (including dysplastic nevi), and four case reports of melanoma emerging during or shortly after MT-II use. |
| Bonchev, 2026 | Oral mucosal changes | Case report documenting pigmentary changes in oral mucosa associated with MT-II injections. |
| Burian & Jemec, 2019 | Eruptive melanocytic nevi | Review documenting MT-II as a cause of sudden appearance of multiple new moles. |
| Reid & Leong, 2012 | Rhabdomyolysis | Case of rhabdomyolysis and acute renal failure following MT-II injection in a bodybuilder. |
Sources: Peters et al., 2020 · Habbema et al., 2017 · Bonchev, 2026 · Burian & Jemec, 2019
User Surveys
Several survey-based studies have characterized the MT-II user population and reported side effects:
- Brennan et al., 2009: Survey of 21 MT-II users in the UK. All reported tanning. 86% reported nausea. 71% of men reported spontaneous erections. 48% reported facial flushing. 29% noted mole darkening or new mole formation. Users obtained the product from internet sources and self-injected (Brennan et al., 2009).
- Cousen & Sheridan, 2014: Survey of dermatology clinic patients who disclosed MT-II use. Common motivations: cosmetic tanning (92%), desire for a "base tan" before holiday (34%). Most obtained product from gym contacts or internet vendors (Cousen & Sheridan, 2014).
The Melanoma Question
The relationship between Melanotan II and melanoma is the most critical unresolved safety question. The evidence is summarized as follows:
- Theoretical concern: MC1R activation stimulates melanocyte proliferation and melanogenesis. Melanoma arises from melanocytes. Any agent that chronically stimulates melanocytes could theoretically promote melanocyte transformation or accelerate growth of pre-existing melanocytic lesions.
- Case reports: At least four published case reports describe melanomas emerging during or shortly after MT-II use (Habbema et al., 2017).
- Confounding factor: MT-II users are disproportionately drawn from "tanning culture" populations who also use UV tanning beds and have significant sun exposure — both established melanoma risk factors. A 2021 systematic review concluded that the increased melanoma risk in MT-II users "can probably be explained by more UV exposure" rather than MT-II itself (Wensink et al., 2021).
- Bottom line: There is no conclusive evidence that MT-II directly causes melanoma. There is also no evidence that it does not. The studies required to answer this question definitively (large prospective cohorts, long follow-up) have never been conducted and likely never will be, since the compound is unregulated.
The long-term safety of Melanotan II is completely unknown. No long-term studies have been conducted. The existing case report literature represents a fraction of actual adverse events, since most users never report to health authorities. Absence of evidence is not evidence of absence.
Further Reading
This content is for informational purposes only and does not constitute medical advice.
Dosing
Melanotan II is not an approved drug. There is no established safe dose. There is no pharmaceutical-grade product. Any dosing information below is derived from early research data and community reports — not from the rigorous dose-finding studies required for drug approval. Self-administration of unregulated injectable peptides carries risks of infection, contamination, overdose, and unknown long-term harm. GLPbase does not recommend or endorse the use of Melanotan II.
Doses Used in Clinical Research
| Study | Dose | Route | Outcome |
|---|---|---|---|
| Dorr et al., 1996 | 0.010–0.025 mg/kg | SC injection | Dose-dependent tanning. Significant nausea at 0.025 mg/kg. Sexual side effects observed. |
| Dorr et al., 2000 | 0.025 mg/kg daily × 10 days | SC injection | Measurable increase in melanin density. Nausea in 85%. Spontaneous erections common. |
Sources: Dorr et al., 1996 · Dorr et al., 2000
Commonly Reported Community Protocols
The following dosing information is compiled from harm-reduction sources and user reports. It does not represent medical guidance. It is included because people are using this compound regardless of its regulatory status, and accurate information reduces harm.
| Phase | Reported Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| "Loading" | 0.25–0.5 mg | Daily | 2–4 weeks | Users typically start with lower doses (0.1–0.25 mg) to assess tolerance, particularly nausea. Dose gradually increased. |
| "Maintenance" | 0.5–1.0 mg | 1–2×/week | Ongoing | Once desired tanning is achieved, frequency is reduced. Some users combine with brief UV exposure sessions. |
Note: These are community-reported protocols, not clinically validated dosing. Source: harm-reduction literature and user survey data (Brennan et al., 2009).
- No dosing accuracy: Lyophilized powder from grey-market vendors may not contain the stated amount. Independent analyses have found significant variation in peptide content
- No sterility guarantee: Reconstitution with bacteriostatic water requires aseptic technique. Contamination can cause injection-site infections, abscesses, or systemic infection
- No purity verification: Products may contain degradation products, bacterial endotoxins, heavy metals, or entirely different compounds
- Dose-response unpredictability: Individual variation in MC1R polymorphisms means the same dose can produce dramatically different tanning and side effects in different people
Reconstitution and Administration
Melanotan II is typically sold as a lyophilized (freeze-dried) powder in vials of 5 mg or 10 mg. Users reconstitute with bacteriostatic water and inject subcutaneously (usually into abdominal fat). Key points from harm-reduction perspective:
- Storage: Unreconstituted powder should be refrigerated. Reconstituted solution should be refrigerated and used within 4–6 weeks. Product degrades at room temperature.
- Injection technique: Subcutaneous injection into the abdomen using insulin syringes. Proper injection technique and site rotation are critical to reducing infection risk.
- Needle safety: Never share needles. Use new sterile needles for each injection. Dispose of sharps properly.
This dosing information is provided for harm reduction only. GLPbase does not recommend or endorse the use of Melanotan II.
Safety
Melanotan II has undergone only preliminary clinical testing. There is no post-marketing surveillance system, no pharmacovigilance program, and no systematic collection of adverse event data. The side effects listed below are drawn from limited clinical trials, case reports, and user surveys — they almost certainly underrepresent the true scope and frequency of adverse events.
Common Side Effects
| Side Effect | Reported Frequency | Notes |
|---|---|---|
| Nausea | 40–85% | Dose-dependent. Typically most severe with initial doses and diminishes with continued use. Can be severe enough to cause vomiting. |
| Facial flushing | 30–50% | Warmth and redness of the face. Usually transient (30–60 min post-injection). |
| Spontaneous erections (men) | 50–70% | Can occur without sexual stimulation. Usually within 1–3 hours of injection. May be prolonged. |
| Mole darkening | 30–50% | Existing moles, freckles, and nevi become noticeably darker. One of the most clinically significant effects. |
| New mole formation | 10–30% | Appearance of new nevi, including dysplastic (atypical) nevi. |
| Appetite suppression | 20–40% | MC4R-mediated. Can be significant. Some users report this as a desired effect. |
| Fatigue / drowsiness | 15–30% | Often follows initial nausea and flushing. |
| Yawning / stretching | 10–20% | Characteristic of melanocortin activation. Reported in clinical studies. |
Frequency estimates compiled from: Dorr et al., 2000 · Brennan et al., 2009 · Habbema et al., 2017
Serious Safety Concerns
Melanotan II darkens existing moles and can cause new moles to form — including atypical (dysplastic) nevi. This creates a direct conflict with melanoma screening, which relies on detecting changes in moles (the ABCDE criteria: asymmetry, border, color, diameter, evolution). When all moles are uniformly darker and new moles are appearing, it becomes significantly harder for dermatologists to identify malignant changes. Users who have used MT-II should disclose this to any dermatologist performing a skin examination.
By chronically stimulating MC1R on melanocytes, Melanotan II may theoretically promote melanocyte proliferation and lower the threshold for malignant transformation. At least four published case reports describe melanoma developing during or shortly after MT-II use. While causation has not been established, the biological mechanism is plausible. No long-term studies exist to quantify this risk (Habbema et al., 2017).
MC4R activation can cause prolonged erections (priapism) — a medical emergency defined as an erection lasting more than 4 hours. Priapism requires emergency urological intervention to prevent permanent tissue damage and erectile dysfunction. Cases have been reported with MT-II, particularly at higher doses or when combined with PDE5 inhibitors (Viagra, Cialis) (Hadley & Dorr, 2006).
All Melanotan II available to consumers comes from unregulated sources. Independent laboratory analyses of grey-market peptides have found:
- Significant under- or over-dosing relative to label claims
- Bacterial contamination including endotoxins
- Degradation products and oxidized peptide fragments
- In some cases, entirely different compounds than labeled
- Heavy metal contamination from uncontrolled manufacturing
There is no pharmaceutical-grade Melanotan II available anywhere in the world (Janvier et al., 2018).
Reported Serious Adverse Events
| Event | Reference | Details |
|---|---|---|
| Renal infarction | Peters et al., 2020 | Thrombotic event attributed to MT-II. Possible pharmacological vasoconstrictive or prothrombotic effect. |
| Rhabdomyolysis | Multiple case reports | Muscle breakdown leading to acute kidney injury. Mechanism unclear — may relate to contamination or idiosyncratic reaction. |
| Melanoma (case reports) | Habbema et al., 2017 | Four documented cases. Causation not established; users had concurrent UV exposure. |
| Oral mucosal pigmentation | Bonchev, 2026 | Pigmentary changes in gums and oral mucosa that may mimic pathological conditions. |
| Injection site infections | Multiple reports | Abscesses and cellulitis from non-sterile injection technique or contaminated product. |
Sources: Peters et al., 2020 · Habbema et al., 2017 · Bonchev, 2026
Blood Pressure Effects
Melanotan II can cause transient blood pressure changes. In the related compound PT-141, intranasal administration caused sufficient blood pressure increases to trigger an FDA clinical hold. The subcutaneous route produces smaller increases, but MT-II's non-selective receptor activation may cause greater cardiovascular effects than the more selective PT-141. Individuals with hypertension or cardiovascular disease face elevated risk (Safarinejad, 2008).
Long-Term Safety: Unknown
Perhaps the most important safety statement about Melanotan II is the simplest: the long-term safety profile is completely unknown. No studies have followed MT-II users for years or decades. The effects of chronic melanocyte stimulation over a lifetime — on melanoma risk, cardiovascular health, renal function, reproductive health, or any other organ system — have not been studied. Users are participating in an uncontrolled, unmonitored experiment on themselves.
Further Reading
This content is for informational purposes only and does not constitute medical advice.
Cost
Typical Pricing
| Source | Typical Price | What You Get | Quality Assurance |
|---|---|---|---|
| Grey-market "research chemical" vendors | $20–60 per 10 mg vial | Lyophilized powder. Requires reconstitution with bacteriostatic water. Labeled "not for human consumption." | None. No regulatory oversight, no third-party testing required, no manufacturing standards. |
| "Peptide clinics" / anti-aging clinics | $100–300 per course | May include reconstituted product, syringes, and dosing guidance. Some clinics provide provider oversight. | Variable. Depends on whether the clinic sources from a licensed compounding pharmacy or grey-market vendors. |
| International pharmacies (grey market) | $15–40 per 10 mg vial | Bulk pricing available. Quality is entirely vendor-dependent. | None. Same unregulated supply chain as direct vendors. |
Additional Costs
- Bacteriostatic water: $5–15 per vial (required for reconstitution)
- Insulin syringes: $10–20 per box of 100
- Sharps disposal container: $5–10
- Dermatology screening: $150–400 per visit (recommended for anyone who has used MT-II, to monitor for melanocytic changes)
The Hidden Cost Problem
The low sticker price of MT-II is frequently cited by users as an advantage over professional spray tans or tanning bed memberships. However, this comparison omits critical factors:
- No quality guarantee: When a 10 mg vial costs $30, the manufacturing cost to the vendor is a fraction of that. Quality control — HPLC purity testing, endotoxin testing, sterility testing — adds cost that most vendors do not absorb. You are paying for a product with no verified contents.
- Medical costs: Adverse events (infections, rhabdomyolysis, renal complications, melanoma) can result in medical costs orders of magnitude higher than the product itself.
- Insurance implications: Health insurance typically does not cover complications arising from self-administration of unregulated substances, potentially leaving users liable for full medical costs.
This content is for informational purposes only and does not constitute medical advice.
Comparisons
Melanotan II vs. Natural Tanning (UV Exposure)
| Factor | Melanotan II | Natural Tanning (Sun / Tanning Beds) |
|---|---|---|
| Mechanism | Pharmacological MC1R activation → melanin production | UV radiation → DNA damage → melanin production as protective response |
| UV exposure required | Not required, though some users combine with minimal UV for faster results | Required. Cumulative UV exposure is the primary cause of skin aging and skin cancer |
| Skin cancer risk | Unknown. Theoretical melanoma promotion via chronic melanocyte stimulation. No long-term data. | Well-established. UV causes direct DNA damage. Tanning bed use before age 35 increases melanoma risk by 59% |
| Skin aging | No direct photoaging effect (no UV component) | UV is the primary driver of premature skin aging (wrinkles, spots, loss of elasticity) |
| Regulatory status | Not approved. Unregulated. | Legal. Tanning beds regulated in many jurisdictions (age restrictions, warning requirements) |
| Mole changes | Common. Darkens existing moles, creates new ones. Complicates skin cancer screening. | Can darken moles with extensive exposure, but less dramatically |
| Side effects | Nausea, flushing, erections, appetite changes, contamination risk | Sunburn, photoaging, immunosuppression |
Melanotan II vs. Spray Tans (DHA-Based)
| Factor | Melanotan II | Spray Tan (Dihydroxyacetone / DHA) |
|---|---|---|
| Mechanism | Systemic peptide → actual melanin production in melanocytes | Topical DHA reacts with amino acids in dead skin cells (stratum corneum) → surface color change (Maillard reaction) |
| Duration | Weeks to months with maintenance dosing | 5–10 days (fades as skin naturally exfoliates) |
| Depth of tan | True melanin-based pigmentation. Appears natural. Develops gradually. | Surface-level. Can appear orange if poorly applied. Does not produce real melanin. |
| UV protection | Real melanin provides some photoprotection (though not a substitute for sunscreen) | No UV protection. DHA-based color provides zero sun protection. |
| Safety profile | Unknown long-term safety. Injection-related risks. Systemic effects. | Well-established safety. Topical only. FDA lists DHA as approved for external cosmetic use. |
| Cost | $20–60/vial + supplies | $25–50 per professional application; $10–30 for at-home products |
| Regulatory status | Not approved | Approved cosmetic ingredient |
Melanotan II vs. PT-141 (Bremelanotide)
| Factor | Melanotan II | PT-141 (Bremelanotide / Vyleesi) |
|---|---|---|
| Receptor selectivity | Non-selective (MC1R, MC3R, MC4R, MC5R) | MC4R-preferring (reduced MC1R activity) |
| Primary effect | Tanning (MC1R) + sexual arousal (MC4R) | Sexual arousal (MC4R) |
| Tanning effect | Significant | Minimal (some hyperpigmentation possible with frequent use) |
| Sexual effects | Significant but uncontrolled | Clinically validated for HSDD in women |
| Clinical evidence | Phase I only. Case reports and surveys. | Phase 3 trials. 1,200+ patients. FDA-reviewed. |
| FDA status | Not approved | Approved (2019) as Vyleesi for HSDD |
| Manufacturing | Grey market. No quality control. | cGMP pharmaceutical manufacturing (Vyleesi). Also available from compounding pharmacies. |
| Nausea rate | 40–85% (dose-dependent) | ~40% (at approved dose) |
| Cost | $20–60/vial (unregulated) | $200–900/month (pharmaceutical) |
Sources: Molinoff et al., 2003 · Kingsberg et al., 2019 · Dorr et al., 2000
Key Takeaway
If the primary goal is cosmetic tanning, DHA-based spray tans offer a known-safe, regulated, topical alternative with no systemic effects. If the primary goal is sexual function, PT-141 (bremelanotide) offers an FDA-approved, clinically validated alternative with known dosing, manufacturing quality, and safety data. Melanotan II occupies an unapproved middle ground that delivers both effects with neither the safety data nor the quality controls of either alternative.
This content is for informational purposes only and does not constitute medical advice.
Questions & Answers
Myth: Melanotan II is safe because it is "natural" — it is just a version of a hormone your body already makes.
Answer: While MT-II is structurally based on α-MSH (a naturally occurring hormone), it is a synthetic analogue with significantly different properties. It has been engineered for increased potency, metabolic stability, and receptor binding — it is far more powerful and longer-lasting than natural α-MSH. It also activates multiple receptor subtypes non-selectively, whereas the body's own melanocortin signaling is tightly regulated through local concentrations, receptor expression patterns, and endogenous antagonists (e.g., agouti signaling protein). Calling MT-II "natural" is like calling synthetic anabolic steroids "natural" because testosterone exists in the body (Hadley & Dorr, 2006).
Myth: Melanotan II protects against skin cancer by building a tan without UV damage.
Answer: This was the original research hypothesis — and it is unproven and potentially backwards. While melanin does provide some UV photoprotection, MT-II simultaneously stimulates melanocyte proliferation, darkens existing moles, creates new nevi (including atypical ones), and makes melanoma screening harder. The net effect on skin cancer risk is unknown. No study has demonstrated that MT-II reduces skin cancer incidence. The theoretical concern that chronic melanocyte stimulation could promote melanoma has not been ruled out (Habbema et al., 2017).
Question: Is Melanotan II the same as Melanotan I (afamelanotide)?
Answer: No. They are distinct compounds with different structures, receptor profiles, and regulatory statuses. Afamelanotide (Melanotan I, marketed as Scenesse) is an MC1R-selective linear peptide that is FDA-approved for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme photosensitivity. It produces tanning without the sexual side effects, nausea profile, or melanocytic concerns associated with MT-II. Melanotan II is a cyclic heptapeptide with non-selective melanocortin activity and no regulatory approval. They should not be confused (Habbema et al., 2017).
Myth: The mole darkening from Melanotan II is harmless and purely cosmetic.
Answer: Mole darkening from MT-II reflects actual melanocyte stimulation and increased melanin production within nevi. This is not a surface-level cosmetic effect — it is a biological change in melanocytes, the same cells from which melanoma arises. Additionally, the formation of new nevi (including dysplastic nevi) has been documented. Even if these changes are ultimately benign in most users, they make melanoma screening significantly more difficult by obscuring the clinical changes (evolution in color, size, and shape) that dermatologists rely on to detect early melanoma. This is a real clinical harm, not a theoretical one (Burian & Jemec, 2019).
Question: Can I use Melanotan II if I have fair skin and do not tan naturally?
Answer: Fair-skinned individuals (Fitzpatrick Type I–II) are the population most interested in MT-II, as they are least able to tan naturally. Ironically, they are also the population at highest baseline risk for melanoma — and the population in whom the theoretical risks of chronic melanocyte stimulation are most concerning. Fair skin often reflects MC1R polymorphisms (particularly the R151C, R160W, and D294H variants) that reduce baseline MC1R signaling. MT-II can override these polymorphisms pharmacologically, but the long-term consequences of doing so are completely unknown. Fair-skinned individuals are the demographic that most needs caution with this compound, not least.
Question: How long does the tan from Melanotan II last?
Answer: The tanning effect from MT-II typically begins to appear within 1–2 weeks of regular use and can persist for weeks to months after discontinuation, as the melanin produced is real pigment deposited in the skin. The duration depends on the extent of loading, individual melanocyte responsiveness, and rate of skin cell turnover. Maintenance doses (typically 1–2 times per week) are used to sustain the effect. Without maintenance, the tan gradually fades over 1–3 months as melanin-containing cells are naturally shed (Dorr et al., 2000).
Question: Is Melanotan II legal?
Answer: The legal status is complex and varies by jurisdiction. In most countries, MT-II is not a controlled substance, but it is also not an approved drug. It occupies a regulatory grey area — it is typically sold labeled as a "research chemical" with disclaimers that it is "not for human consumption." Purchasing it is generally not illegal for the buyer, but selling it for human use would violate pharmaceutical regulations in most jurisdictions. Health agencies in the US (FDA), UK (MHRA), Australia (TGA), and EU (EMA) have issued warnings advising consumers not to use it. The product is explicitly prohibited by WADA for athletes.
Myth: Nausea from Melanotan II means you are taking too much — just lower the dose.
Answer: Nausea is an intrinsic pharmacological effect of MC4R activation, not a sign of overdose. While it is dose-dependent (higher doses cause more nausea), it occurs at all effective doses in a substantial proportion of users. In the Dorr et al. (2000) study using carefully measured pharmaceutical-grade MT-II at 0.025 mg/kg, 85% of subjects experienced nausea. Dose reduction may reduce nausea severity but does not eliminate it, and lower doses may not produce the desired tanning effect. The nausea reflects the same receptor activation that produces the sexual and appetite effects — it cannot be pharmacologically separated from them with a non-selective agonist (Dorr et al., 2000).
Further Reading
This content is for informational purposes only and does not constitute medical advice.
Sources & Further Reading
Clinical Trials and Original Research
- Dorr RT, Lines R, Levine N, et al. (1996) — "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study" — Life Sciences
- Dorr RT, Dvorakova K, Brooks C, et al. (2000) — "Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-α-MSH in humans" — Photochemistry and Photobiology
- Diamond LE, Earle DC, Heiman JR, et al. (2005) — "Bremelanotide (PT-141): a melanocortin receptor agonist for erectile dysfunction" — International Journal of Impotence Research
Review Articles
- Hadley ME, Dorr RT (2006) — "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization" — Peptides
- Habbema L, Halk AB, Neumann M, Bergman W (2017) — "Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review" — International Journal of Dermatology
- Wensink D, et al. (2021) — "Melanoma risk in Melanotan users: systematic review"
- Burian EA, Jemec GBE (2019) — "Eruptive melanocytic nevi: a review" — American Journal of Clinical Dermatology
- Wikberg JES, et al. (2001) — "New aspects on the melanocortins and their receptors" — Pharmacological Research
Case Reports
- Peters B, Hadimeri H, Wahlberg R, Afghahi H (2020) — "Melanotan II: a possible cause of renal infarction" — CEN Case Reports
- Bonchev A (2026) — "Changes in oral mucosa associated with Melanotan II injections: a case report" — Life (Basel)
User Surveys and Epidemiology
- Brennan R, Wells JSG, Van Hout MC (2009) — "The injecting use of image and performance enhancing drugs (IPED) in the general population: a systematic review" — Journal of Substance Use
- Cousen P, Sheridan D (2014) — "Melanotan II use in dermatology clinic patients"
Mechanism and Pharmacology
- Molinoff PB, et al. (2003) — "PT-141: A melanocortin agonist for the treatment of sexual dysfunction" — Annals of the New York Academy of Sciences
- Safarinejad MR (2008) — "Evaluation of bremelanotide, a melanocortin receptor agonist" — Journal of Sexual Medicine
Product Quality and Regulation
Regulatory Warnings
- FDA — Warning on tainted and unapproved products
- TGA (Australia) — Safety alert on Melanotan products
- WADA — Prohibited List (current year)
Related GLPbase Articles
- PT-141 (Bremelanotide): The Complete Guide — FDA-approved derivative of Melanotan II for sexual dysfunction
This content is for informational purposes only and does not constitute medical advice.
